Revance Therapeutics Inc
RVNC
ISIN null / Valor 23239569
Revance Therapeutics Inc
UMushroom community rating:
About company
Revance Therapeutics Inc. is a biotechnology firm that specializes in the development and commercialization of innovative neuromodulator products for various therapeutic and aesthetic applications. The company has entered into strategic partnerships to expand its global footprint, notably with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (Fosun Pharma Industrial), granting Fosun Pharma Industrial exclusive rights to develop and commercialize Revance's daxibotulinumtoxinA-lanm injection in mainland China, Hong Kong, and Macau. This collaboration has led to the initiation of Phase 3 trials in China for the treatment of glabellar lines and cervical dystonia. Additionally, Revance is working with Viatris Inc. to develop a biosimilar to BOTOX®, aiming to compete in the short-acting neuromodulator market while also establishing a new category for longer-acting neuromodulators. This strategic approach underscores Revance's commitment to innovation and expanding access to its neuromodulator products in key markets worldwide.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
756 M
Market cap (USD)
Daily traded volume (Shares)
3.07 / 3.06
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
